65 related articles for article (PubMed ID: 26369711)
1. In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146.
Ong VA; Lawrence A; Timms P; Vodstrcil LA; Tabrizi SN; Beagley KW; Allan JA; Hocking JS; Huston WM
Microbes Infect; 2015; 17(11-12):738-44. PubMed ID: 26369711
[TBL] [Abstract][Full Text] [Related]
2. The protease inhibitor JO146 demonstrates a critical role for CtHtrA for Chlamydia trachomatis reversion from penicillin persistence.
Ong VA; Marsh JW; Lawrence A; Allan JA; Timms P; Huston WM
Front Cell Infect Microbiol; 2013; 3():100. PubMed ID: 24392355
[TBL] [Abstract][Full Text] [Related]
3. CtHtrA: the lynchpin of the chlamydial surface and a promising therapeutic target.
Marsh JW; Ong VA; Lott WB; Timms P; Tyndall JD; Huston WM
Future Microbiol; 2017 Jul; 12():817-829. PubMed ID: 28593794
[TBL] [Abstract][Full Text] [Related]
4. Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to Chlamydia trachomatis.
Gloeckl S; Ong VA; Patel P; Tyndall JD; Timms P; Beagley KW; Allan JA; Armitage CW; Turnbull L; Whitchurch CB; Merdanovic M; Ehrmann M; Powers JC; Oleksyszyn J; Verdoes M; Bogyo M; Huston WM
Mol Microbiol; 2013 Aug; 89(4):676-89. PubMed ID: 23796320
[TBL] [Abstract][Full Text] [Related]
5. Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues.
Hwang J; Strange N; Phillips MJA; Krause AL; Heywood A; Gamble AB; Huston WM; Tyndall JDA
Eur J Med Chem; 2021 Nov; 224():113692. PubMed ID: 34265463
[TBL] [Abstract][Full Text] [Related]
6. Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection.
Lawrence A; Fraser T; Gillett A; Tyndall JD; Timms P; Polkinghorne A; Huston WM
Sci Rep; 2016 Aug; 6():31466. PubMed ID: 27530689
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity analysis of peptidic Chlamydia HtrA inhibitors.
Agbowuro AA; Hwang J; Peel E; Mazraani R; Springwald A; Marsh JW; McCaughey L; Gamble AB; Huston WM; Tyndall JDA
Bioorg Med Chem; 2019 Sep; 27(18):4185-4199. PubMed ID: 31395511
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a conserved role for Chlamydia HtrA in the replication phase of the chlamydial developmental cycle.
Patel P; De Boer L; Timms P; Huston WM
Microbes Infect; 2014 Aug; 16(8):690-4. PubMed ID: 25066238
[TBL] [Abstract][Full Text] [Related]
9. A novel protease inhibitor causes inclusion vacuole reduction and disrupts the intracellular growth of Chlamydia trachomatis.
Zhou Y; Lu X; Huang D; Lu Y; Zhang H; Zhang L; Yu P; Wang F; Wang Y
Biochem Biophys Res Commun; 2019 Aug; 516(1):157-162. PubMed ID: 31202460
[TBL] [Abstract][Full Text] [Related]
10. A Chlamydia trachomatis strain with a chemically generated amino acid substitution (P370L) in the cthtrA gene shows reduced elementary body production.
Marsh JW; Wee BA; Tyndall JD; Lott WB; Bastidas RJ; Caldwell HD; Valdivia RH; Kari L; Huston WM
BMC Microbiol; 2015 Sep; 15():194. PubMed ID: 26424482
[TBL] [Abstract][Full Text] [Related]
11. Proteolytic activation of Chlamydia trachomatis HTRA is mediated by PDZ1 domain interactions with protease domain loops L3 and LC and beta strand β5.
Marsh JW; Lott WB; Tyndall JD; Huston WW
Cell Mol Biol Lett; 2013 Dec; 18(4):522-37. PubMed ID: 24036669
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of P2-modified proline analogues targeting the HtrA serine protease in Chlamydia.
Hwang J; Strange N; Mazraani R; Phillips MJ; Gamble AB; Huston WM; Tyndall JDA
Eur J Med Chem; 2022 Feb; 230():114064. PubMed ID: 35007862
[TBL] [Abstract][Full Text] [Related]
13. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
[TBL] [Abstract][Full Text] [Related]
14. [Minimum inhibitory concentration and minimum bactericidal concentration of tetracycline and erythromycin in 35 recent Munich isolates of Chlamydia trachomatis].
Korting HC; Hartinger A
Hautarzt; 1988 Mar; 39(3):161-5. PubMed ID: 3378887
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intracellular multiplication of human strains of Chlamydia trachomatis by nitric oxide.
Igietseme JU; Uriri IM; Chow M; Abe E; Rank RG
Biochem Biophys Res Commun; 1997 Mar; 232(3):595-601. PubMed ID: 9126319
[TBL] [Abstract][Full Text] [Related]
16. the active site residue V266 of Chlamydial HtrA is critical for substrate binding during both in vitro and in vivo conditions.
Gloeckl S; Tyndall JD; Stansfield SH; Timms P; Huston WM
J Mol Microbiol Biotechnol; 2012; 22(1):10-6. PubMed ID: 22353774
[TBL] [Abstract][Full Text] [Related]
17. Kinetic characterization of alkaline mesentericopeptidase. Comparison with serine proteinases from different origins.
Dolaschka P; Genov N; Ermer A; Peters K; Fittkau S
Int J Pept Protein Res; 1993 Dec; 42(6):560-4. PubMed ID: 8307687
[TBL] [Abstract][Full Text] [Related]
18. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India.
Bhengraj AR; Vardhan H; Srivastava P; Salhan S; Mittal A
Chemotherapy; 2010; 56(5):371-7. PubMed ID: 20938174
[TBL] [Abstract][Full Text] [Related]
19. The molecular biology and diagnostics of Chlamydia trachomatis.
Birkelund S
Dan Med Bull; 1992 Aug; 39(4):304-20. PubMed ID: 1526183
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
